TROPION-Breast04: A phase 3 study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab vs the standard of care in treatment-naive early-stage triple negative or HR-low/HER2-breast cancer

被引：0
|
作者：
McArthur, Heather
Tolaney, Sara
Loibl, Sibylle
Dent, Rebecca
Schmid, Peter
Asselah, Jamil
Song, Erwei
Niikura, Naoki
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-20-13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-20-13
引用
收藏
页数：3
相关论文
共 36 条
  • [31] Platinum compounds (PLcs) added to standard adjuvant or neoadjuvant regimen of biweekly doxorubicin plus cyclophosphamide (AC), followed by weekly paclitaxel (wP) in triple-negative (TN), HER2-neu-positive (HER2+), or locally advanced breast cancer (LABC): Preliminary results of a prospective, phase II, nonrandomized study.
    Vassilaki, M.
    Sioulas, A.
    Tsantekidou, M.
    Klitsa, A.
    Desses, N.
    Georgakopoulos, C.
    Thomou, P.
    Xepapadakis, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] EarLEE-2: A phase 3 study of ribociclib plus endocrine therapy (ET) for adjuvant treatment of patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), intermediate-risk, early breast cancer (EBC)
    O'Shaughnessy, Joyce
    Alba, Emilio
    Bardia, Aditya
    Dent, Susan
    Dieras, Veronique
    Hortobagyi, Gabriel
    Im, Seock-Ah
    Montemurro, Filippo
    Untch, Michael
    Yardley, Denise A.
    Chakravartty, Arunava
    Germa, Caroline
    Miller, Michelle
    Slamon, Dennis
    CANCER RESEARCH, 2018, 78 (04)
  • [33] A Phase 3, randomized, open-label study of upfront camizestrant vs standard endocrine therapy as adjuvant treatment for ER-positive/HER2negative early breast cancer with intermediate-high or high risk of recurrence (CAMBRIA-2)
    Loibl, Sibylle
    Park, Yeon
    Tolaney, Sara
    Gioni, Ioanna
    Johnston, Simon
    Klinowska, Teresa
    Mayer, Ingrid A.
    Nunes, Raquel
    Pistilli, Barbara
    Stuart, Mary
    Quintana, Angela
    Walding, Andrew
    Gnant, Michael
    CANCER RESEARCH, 2024, 84 (09)
  • [34] KEYNOTE-756: Randomized, double-blind, phase III study of pembrolizumab vs placebo plus neoadjuvant chemotherapy (CT) and adjuvant endocrine therapy (ET) for high-risk, early-stage estrogen receptor-positive human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer (BC)
    Cardoso, F.
    Jia, L.
    Hirshfield, K.
    Karantza, V.
    ANNALS OF ONCOLOGY, 2019, 30 : 38 - 38
  • [35] KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.
    Cardoso, Fatima
    Bardia, Aditya
    Andre, Fabrice
    Cescon, David W.
    McArthur, Heather L.
    Telli, Melinda L.
    Loi, Sherene
    Cortes, Javier
    Schmid, Peter
    Harbeck, Nadia
    Denkert, Carsten
    Jackisch, Christian
    Jia, Liyi
    Hirshfield, Kim M.
    Karantza, Vassiliki
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] EarLEE-1: A phase 3 study of ribociclib plus endocrine therapy (ET) for adjuvant treatment of patients (pts) with hormone receptor-positive (HR1), human epidermal growth factor receptor 2-negative (HER2-), high-risk, early breast cancer (EBC)
    Martin Jimenez, M.
    Bachelot, T.
    Barrios, C.
    Blackwell, K.
    Chia, S.
    De Laurentiis, M.
    Hurvitz, S.
    Janni, W.
    Kaufman, B.
    Loi, S.
    Schmid, P.
    Slamon, D.
    Hazell, K.
    Mondal, S.
    Shilkrut, M.
    Germa, C.
    Hortobagyi, G.
    ANNALS OF ONCOLOGY, 2017, 28
1234